Biomerica, Inc.
As of Oct 22, 2026, Biomerica is in Stage 1, the basing phase, now in week 6 (since Sep 14, 2026). It closed at $1.68, 43.2% below its 52-week high and below its 200-day average, which is falling.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical condi… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BMRA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BMRA among Medical Devices86th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …86 | BMRA | Stage 1 · wk 6 | 25 | −35.6% |
Biomerica: quick answers
What stage is Biomerica in?
As of Oct 22, 2026, Biomerica (BMRA) is in Stage 1, the basing phase. It entered Stage 1 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Biomerica in an uptrend?
Not yet. Biomerica is in Stage 1, a base that can come before an uptrend. It trades 19.2% below its 200-day average, which is falling.
How far is Biomerica from its 52-week high?
Biomerica closed at $1.68 on Oct 22, 2026, 43.2% below its 52-week high of $2.96. Its 52-week low is $1.49.
How has Biomerica performed over the past year?
As of Oct 22, 2026, Biomerica is down 47.5% over the past year and down 33.6% so far in 2026.
Which sector and industry is Biomerica in?
Biomerica is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.